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This phase II trial describes the use of TIP chemotherapy (paclitaxel, ifosfamide and cisplatin) as salvage for patients with metastatic
germ cell cancer (GCC) who have failed initial BEP (bleomycin, etoposide and cisplatin) chemotherapy. Patients with first relapse
following BEP for metastatic GCC, confirmed by biopsy or sequentially rising markers, received four courses of TIP (paclitaxel
175mgm
 2 day 1, followed on days 1–5 by ifosfamide 1gm
 2 intravenously (i.v.) and cisplatin 20mg
2 i.v.) at 3-weekly intervals. The
primary outcome measure was response to TIP. In all, 51 patients were registered, of whom 43 were eligible for response
assessment. Eight achieved complete remission (CR) and 18 a partial remission with negative markers (PR
 ve); favourable response
rate (FRR¼CRþPR
 ve) 60%, 95% CI (44–75%); survival at 1 year was 70% (56–84%) and failure-free survival 36% (22–50%). In
the group of 26 patients meeting the ‘good-risk’ criteria described by the Memorial Hospital, the FRR was 73% (52–88%) compared
with 41% (18–67%) for the 17 ‘poor-risk’ patients. These results are inferior to those previously reported for TIP in a single-centre
study when it was given more intensively, at higher dose and with growth factor support. Nonetheless, TIP as described here can cure
a substantial proportion of patients.
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Approximately 85% of patients with newly diagnosed metastatic
germ cell cancer (GCC) will be cured when treated with a cisplatin-
containing regimen7surgery; BEP (bleomycin etoposide and
cisplatin) is currently the worldwide standard treatment. The
remaining 15% of patients require salvage treatment and are a
relatively heterogeneous group. A proportion may be salvaged
surgically, predominantly patients with recurrent mature teratoma
or with a late relapse (Baniel et al, 1995; Gerl et al, 1997). However,
most will require chemotherapy.
Two treatment approaches have been used in this population:
standard-dose chemotherapy given alone, or standard dose in
combination with high-dose chemotherapy plus autologous stem
cell rescue. A preliminary analysis of a single randomised trial
comparing these approaches has been reported and has shown no
difference in survival (Rosti et al, 2002).
A variety of prognostic factors determine outlook in these
patients (Motzer et al, 1991; Gerl et al, 1995; Miller et al, 1997;
Loehrer et al, 1998; Fossa et al, 1999). The Memorial Hospital
Group (MSKCC) divided their population into two groups with
a good or poor prognosis (Motzer et al, 1991, 2000a,b; Donadio
et al, 2003). The former group, defined by the presence of a
testicular primary, p6 cycles of cisplatin-containing chemo-
therapy and initial complete response or partial response with
normal tumour markers, was evaluated in a phase II study of TIP
(paclitaxel, ifosfamide and cisplatin (Motzer et al, 2000b). Initial
and updated (Donadio et al, 2003) results suggest high efficacy for
this treatment approach in this group of patients.
The multi-institution study described here has evaluated TIP
given at modified dose in a salvage setting to all prognostic groups
and has compared the results with the MSKCC salvage chemo-
therapy experience.
PATIENTS AND METHODS
Eligibility
Male patients with the following characteristics were eligible: (i)
first relapse after previous BEP chemotherapy given for metastatic
GCC, (ii) either sequentially rising serum markers (AFP and/or
HCG) or biopsy-proven and unresectable GCC; (iii) age 16–65
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syears; (iv) ECOG performance status 0–2; (v) glomerular filtration
rate of X50mlh
 1 and (vi) no evidence of brain metastases.
Patient registration
Following informed consent, patients were registered by telephon-
ing the MRC Clinical Trials Unit (CTU), London prior to starting
treatment. Exceptionally, patients could be registered during the
first cycle of TIP if urgent treatment was required and weekends
or public holidays prevented earlier registration. The treatment
protocol was approved by both national and local Research Ethics
Committees.
Treatment
TIP comprised paclitaxel 175mgm
 2 given intravenously (i.v.)
over 3h after appropriate premedication on day 1, followed
on days 1–5 by ifosfamide 1gm
 2 i.v. over 1h with mesna
500mgm
 2. Following this infusion, a further 500mgm
 2 of
mesna was given in 1l of normal saline over 8h as part of cisplatin
hydration. Patients also received cisplatin 20mgm
 2 i.v. on days
1–5 with appropriate pre- and postcisplatin hydration.
TIP was recommenced on day 22 using the following dose
reduction schedule for ifosfamide and paclitaxel: total WBC
42.0 10
9l
 1 and platelets 4100 10
9l
 1 or WBC43.0 10
9l
 1
and platelets 75–100 10
9l
 1; full doses of all drugs. Total
WBC 41.5 10
9l
 1 and platelets 50–100 10
9l
 1; 75% dose
ifosfamide and paclitaxel. Total WBC 1.5–2 10
9l
 1 and platelets
50–75 10
9l
 1; 50% dose ifosfamide and paclitaxel.
Patients with lower blood counts had chemotherapy deferred for
3 days and were treated according to the above schedule on
recovery of counts. No dose modifications were made based on
previous treatment cycles. Granulocyte colony-stimulating factor
(G-CSF) was given at the discretion of the investigator, but was
recommended for all future cycles following an episode of
neutropenic sepsis.
Cisplatin was given at full dose unless the creatinine clearance
fell below 40mlmin
 1, in which case it was discontinued. If the
creatinine clearance recovered subsequently to above this level,
cisplatin was initially recommenced at 75% dose. Routine
supportive care was offered for neutropenic fever and thrombo-
cytopenia according to the protocols then in use in each
institution.
Clinical evaluation
All patients initially underwent full physical examination together
with assessment of the tumour markers AFP, HCG and LDH. Chest
X-ray and CT scans of the head, chest, abdomen and pelvis were
performed together with routine biochemistry and a 24-h
creatinine clearance (or EDTA). During treatment, the AFP and
HCG levels were monitored together with chest X-rays. At the
completion of chemotherapy, a new CT scan was performed.
Marker negative patients with residual resectable masses were
assessed surgically and, wherever feasible, these were completely
excised.
Response assessment and toxicity evaluation
All patients had to complete at least one course of chemotherapy
before being eligible for response evaluation. Following chemo-
therapy and/or surgery, the following criteria were defined by the
protocol. Complete remission (CR): normal AFP and HCG levels;
no radiological evidence of residual tumour masses or, if surgery
was performed, complete excision of mature teratoma or necrotic/
fibrotic tissue. Incomplete response (IR): persistent elevation of
tumour markers or viable cancer seen in surgically resected
specimens (including those which were completely resected).
Treatment failure: rising tumour markers or radiological progres-
sion during chemotherapy. Partial remission, marker negative;
(PR
 ve): normal tumour markers at completion of chemotherapy
but nonresectable/resected residual tumour masses. Additionally,
the category CR(S) has been used to identify IR patients with no
evidence of disease following complete resection of viable
malignancy. Failure-free survival (FFS) events were defined as
follows: IR/failure of TIP at response assessment (time of failure
was taken to be day 1) excluding CR(S) patients; relapse after CR,
CR(S) or PR
 ve (time of failure was taken to be date of relapse
confirmation); and death from any cause (time of failure was date
of death, if no prior FFS event observed). Patients without an FFS
event were censored at the last assessment date, or start of
consolidation chemotherapy (n¼2). Survival was measured from
the date of initiation of chemotherapy to date of death or date last
seen. Toxicity was evaluated using the NCIC Common Toxicity
Criteria (v2).
Consolidation therapy and follow-up
In this multicentre study, a number of group members reserved the
right to consolidate the treatment results attained with TIP by use of
either high-dose chemotherapy with stem cell rescue or involved-
field radiotherapy (this latter approach was used predominantly for
patients with seminoma and residual masses). High-dose therapy
w a su s e dl e s sf r e q u e n t l ya st h es t u d yp r o g r e s s e d .
On completion of treatment, it was recommended that patients
be seen every 2 months during the first year, every 3 months in
year 2, every 4 months in year 3, every 6 months in year 4 and
annually thereafter.
Statistical considerations
The primary outcome measure was CR rate after four cycles of TIP.
The study was originally designed to accrue, in a single-stage
design, 25 patients assessable for response allowing the CR rate to
be estimated with a standard error of p10%. A CR rate of X60%
with acceptable toxicity was regarded as a suitable target for use of
this combination in further studies. After this study commenced,
the MSKCC Group published a study using the same drugs,
although at different dose, in their good prognosis subgroup
(Motzer et al, 2000b; Donadio et al, 2003). With approval from the
independent Trial Steering Committee, we continued our study
until we had accrued 25 patients matching these favourable
prognosis criteria to see if we could achieve comparable results.
Response rates, FFS and overall survival rates are given with
95% confidence intervals. FFS and overall survival rates are
presented as Kaplan–Meier curves.
RESULTS
Patient characteristics
In all, 51 male patients from 14 UK centres were registered between
April 1998 and October 2002. Initial accrual was slow as the trial
was confined to patients relapsing after initial induction with BEP
within MRC trial TE20 (de Wit et al, 2001), and only later
expanded to include any patient relapsing after BEP. Of the 51
patients, 43 were entered after this change, in July 2000.
Eight of the 51 patients (16%) were excluded from the primary
analysis. Seven were ineligible: four had normal markers with no
biopsy confirmation of active cancer, one had brain metastases,
one was treated as adjuvant following complete resection of active
cancer and one was registered too late (during the third cycle
of chemotherapy)). In addition, one patient developed an
anaphylactic reaction to paclitaxel in the first treatment cycle
and was thereby withdrawn from the study, and inevaluable for
response.
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sAll the following results relate to the 43 eligible patients (26 good
prognosis (Motzer et al, 2000b), 17 poor prognosis (Motzer et al,
2000a)) whose characteristics are shown in Table 1. The population
comprised four patients with early relapse (entering this study p2
months after the start of their last cycle of BEP), nine with late
relapse (X2 years from completion of BEP) and the remaining 30
patients with intermediate relapse. Histology was nonseminoma in
33 (77%), and 37 (86%) had a gonadal primary.
Chemotherapy delivery
In all, 36 patients (84%) received all four cycles of TIP, five patients
received three cycles and one patient two cycles. The final patient
received five cycles of TIP, the final cycle being given in error. The
median (range) time between treatment cycles 1–2, 2–3 and 3–4,
respectively, were 21 days (19–33), 21 days (19–28) and 21 days
(15–49). The proportion of patients receiving 485% of the
individual drugs were 80.5% for cisplatin, 78.1% for ifosfamide
and 78.1% for paclitaxel. The median (range) relative dose
intensity (actual daily dose intensity divided by planned, full dose,
dose intensity over four courses of treatment) was 0.97 (0.58–1.02)
for cisplatin, 1.03 (0.58–0.95) for ifosfamide and 0.95 (0.63–1.03)
for paclitaxel.
Toxicity
One toxic death occurred following the third TIP cycle, the patient
dying from staphylococcal septicaemia while neutropenic. Grade 3
or 4 leucopenia was recorded in 64% of patients, neutropenia in
70% of patients and thrombocytopenia in 35% of patients; 12
patients (28%) had granulocytopenic fever (with neutrophils
o1.0 10
9l
 1).
Response rates, FFS and survival
Eight patients (19%) achieved CR, seven from TIP alone, one from
TIP and complete resection of a necrotic mass. In total, 18 (42%)
achieved PR
 ve (one had resection of one mass with others
observed). Five patients (12%) had CR(S) (of whom two went on
to receive adjuvant etoposide). Eight patients (19%%) had IR (of
whom two underwent partial resections and one a complete
resection of one of several metastatic sites) and three (7%)
treatment failure/early death (one of whom had complete resection
of one of several metastatic sites). The favourable response rate as
defined by the protocol (FRRp¼CRþPR
 ve) was 60%, 95% CI
(44–75%). Including CR(S) patients in the favourable response
category (FRRc), the FRRc¼72% (56–85%).
The corresponding figures according to MSKCC risk group are
shown in Table 2; the overall FRRp was 73% (52–88%) for the
good-risk patients and 41% (18–67%) for the poor-risk group. The
FRRp (95% CI) for the three groups early (n¼4), intermediate
(n¼30) and late relapse (n¼9) were, respectively, 0% (0–60%),
67% (47–83%) and 67% (30–93%).
Adjunctive treatment was given to seven patients (six of whom
were in the favourable prognosis group). Four (three seminoma,
one mixed tumour) achieved PR
 ve status and received radiotherapy
Table 1 Patient characteristics at study entry (n¼43)
Number of patients %
Primary site
Testis 37 86.00
Mediastinal 3 7.00
Retroperitoneal 1 2.30
Not known 2 4.70
Age (years)
Median 34
Minimum 20
Maximum 51
Histology
Seminoma 9 20.90
Nonseminoma 33 76.70
Not known (high HCG, no biopsy) 1 2.30
Sites
Abdominal 24 55.80
Mediastinal 9 20.90
Supraclavicular 6 14.00
Lung 14 32.60
Pleura 2 4.70
Mesenteric 2 4.70
Markers only 3 7.00
Liver 1 2.30
Bone 1 2.30
Kidney 1 2.30
Inguinal nodes 1 2.30
Pelvis 1 2.30
BHCG (IUl
 1)
Median 28
Minimum Normal
Maximum 9944
AFP (KUl
 1)
Median 4
Minimum Normal
Maximum 89000
LDH (IUl
 1)
Median 391
Minimum 133
Maximum 4534
Relapse interval
o2 months 4 9.30
2 months to 2 years 30 69.80
42 years 9 20.90
Table 2 Response rates, FFS and overall survival
Response (N,% )
Group CR PR MK-ve
Complete resection
of viable malignancy
CR(S) IR
Treatment
failure/early
death
Favourable
(CR+PR)
response rate
(FFRp) (95% CI)
Favourable
(CR+PR+CR(S))
response rate
(FFRc) (95% CI)
1-year
FFS rate
(95% CI)
1-year overall
survival rate
(95% CI)
All patients 8 (19%) 18 (42%) 5 (12%) 8 (19%) 4 (9%) 60% (44–75) 72% (56–85) 38% (23–53) 70% (56–84)
MSKCC good risk 7 (27%) 12 (46%) 2 (8%) 3 (12%) 2 (8%) 73% (52–88) 81% (61–93) 43% (23–63) 81% (64–98)
MSKCC poor risk 1 (6%) 6 (35%) 3 (18%) 5 (29%) 2 (12%) 41% (18–67) 59% (33–82) 29% (8–51) 53% (29–77)
CR¼complete response; PR¼partial response; IR¼incomplete response; FFS¼failure-free survival; 95% CI¼95% confidence interval.
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sto residual masses; one achieved PR
 ve status but proceeded to
high-dose therapy with stem cell support; one patient had an IR
(complete resection of viable tumour) and was given adjuvant oral
etoposide and finally one patient had an IR (partial resection of
viable tumour) and had further high-dose chemotherapy. All seven
patients remain alive and progression free.
In all, 28 FFS events have occurred comprising one early toxic
death, 11 IR/failure to TIP (nine have died, one is alive with active
disease, one is alive and disease free), four relapses after CR(S)
(three have died, one is alive with active disease) and 12 relapses
after CR or PR
 ve (five have died, four are alive with active disease,
three are alive and disease free). Thus, 19 patients are alive and
disease free, six are alive with active disease and 18 have died. Of
the four patients currently disease free following an FFS event,
salvage therapy was high-dose chemotherapy (two patients),
gemcitabineþcisplatin (one patient) and surgeryþradiotherapy
(one patient). The median follow-up time of the 25 survivors is 26
months (range 11–70 months).
Overall FFS and FFS by MSKCC risk groups are shown in
Table 2 and Figures 1 and 2. The overall FFS rate at 1 year is 38%
(95% CI 23–53%); the corresponding rates for the good- and poor-
risk subgroups are 43% (23–63%) and 29% (8–51%), respectively.
Overall survival and survival by MSKCC risk groups are shown
in Figures 3 and 4. The overall survival rate at 1 year is 70%
(56–84%) and the 1-year survival rates for the good- and poor-risk
subgroups are 81% (64–98%) and 53% (29–77%), respectively.
Of the nine seminoma patients (five good risk, four poor risk),
six are currently alive and disease free (three received additional
therapy with radiotherapy and one with high-dose chemotherapy
as adjunctive therapy). Of 33 patients with NSGCT, 13 are alive and
disease free.
DISCUSSION
Patients with metastatic GCC developing first progression of active
cancer despite initial cisplatin-containing chemotherapy almost all
require salvage combination chemotherapy. The exceptions are
patients developing late (42 years) relapse with resectable disease
(Baniel et al, 1995; Gerl et al, 1997).
Salvage chemotherapy should be given with curative intent and
published series suggest 20–57% of patients may achieve long-
term disease-free status with this and subsequent salvage therapy
(Motzer et al, 1991, 2000a,b; Pizzocaro et al, 1992; Miller et al,
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Figure 1 Failure-free survival, all eligible patients.
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Figure 2 Failure-free survival by risk group.
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Figure 4 Survival by risk group.
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s1997; Bhatia et al, 2000). Prognostic factors associated with
an improved outlook include gonadal primary site (Motzer et al,
1991; Pizzocaro et al, 1992; McCaffrey et al, 1997; Loehrer
et al, 1998), achievement of initial CR (or PR
 ve status) with
first-line therapy (Motzer et al, 1991; Pizzocaro et al, 1992;
Gerl et al, 1995; McCaffrey et al, 1997; Loehrer et al, 1998; Fossa
et al, 1999), time to relapse (Baniel et al, 1995; Gerl et al, 1995,
1997; Fossa et al, 1999), low serum markers at relapse (Motzer
et al, 1991; Fossa et al, 1999) and (probably) histology, with
seminoma favourable (Miller et al, 1997). These factors vary
greatly in published salvage series, rendering comparison
between regimens impracticable.
Most patients retain cisplatin sensitivity at relapse, and this
drug has remained a cornerstone of salvage regimens. In
early series, cisplatin was combined with vinblastine (or etoposide)
and ifosfamide (VeIP, VIP; Pizzocaro et al, 1992; Farhat et al,
1996; McCaffrey et al, 1997; Miller et al, 1997; Loehrer et al, 1998),
and numerous series have reported cure rates of 15–42% with
these combinations used alone or with surgery in patients
with NSGCT (Pizzocaro et al, 1992; McCaffrey et al, 1997; Loehrer
et al, 1998).
The obvious need to improve these results has yielded two
different strategies: the increasing use of new drugs with paclitaxel
(Motzer et al, 1994; Bokemeyer et al, 1996; Sandler et al, 1998),
gemcitabine (Bokemeyer et al, 1999; Einhorn et al, 1999),
oxaliplatin (Kollmannsberger et al, 2002a), irinotecan (Kollmanns-
berger et al, 2002b; Miki et al, 2002) and epirubicin (Madani
et al, 2003) currently under evaluation as single agents or in
combination (Hinton et al, 2002; Miki et al, 2002; Kollmannsberger
et al, 2004), and the development of high-dose chemo-
therapy, particularly since the advent of autologous stem cell
rescue and growth factor support (Motzer et al, 1992, 2000a;
Beyer et al, 1997; Bhatia et al, 2000; Rosti et al, 2002;
Kollmannsberger et al, 2004).
The initial approach to salvage chemotherapy has varied from
centre to centre, although the increasing safety of high-dose
treatment has led to a number of centres, including Indiana,
recommending this as initial salvage treatment. This has the
advantage of an increased likelihood of achieving cure compared
with third-line or later use of high-dose therapy (Rick et al, 2001),
but the disadvantage of poor tolerance of subsequent salvage
chemotherapy for the 40–50% of patients destined to fail this
treatment approach (Pont et al, 1997; Beyer et al, 2002). It also
represents overtreatment for the 50–60% of good prognosis
patients who would have been cured with standard-dose treatment
(Fossa et al, 1999).
One, two or multiple cycles of high-dose therapy using a variety
of two or three drug regimens have been used in a phase II setting.
However, a single randomised trial (IT94) under the auspices of
the European Bone Marrow Transplant Group has provided
sobering data (Rosti et al, 2002). A total of 280 patients with
cisplatin-sensitive disease were randomised to four cycles of VIP/
VeIP or three cycles of this treatment followed by high-dose
chemotherapy with carbopec (high-dose carboplatin, etoposide
and cyclophosphamide) with stem cell rescue. The 1-year event-
free survival and 3-year survival (52% in both arms) were
essentially identical.
The alternative approach is standard-dose chemotherapy
incorporating newer drugs. The most commonly evaluated regi-
men is TIP. The MSKCC used this regimen in 30 patients (Motzer
et al, 2000b) – now updated to 46 patients (Donadio et al,2 0 0 3 )–i n
a good prognosis group but at higher doses than those reported
here (paclitaxel 250mgm
 2 by 24-h infusion, ifosfamide 6gmm
 2
in divided dose) and at higher intensity, as no dose reductions
were made and G-CSF was routinely administered. Whereas all
patients in the MRC study had failed BEP, the previous treatment
given to the MSKCC patients was more heterogeneous and was
carboplatin based in two cases.
The MSKCC results were superior when compared with those
described here in a broadly comparable, good-risk group with
longer follow-up. In the updated study report published to date
only in abstract form (Donadio et al, 2003), 46 patients received
TIP (41 nonseminoma, five seminoma), 16 in the setting of late
relapse. In all, 32 patients achieved CR (70%) and two PR
 ve, with
a total favourable response rate of 74%. Three patients relapsed
and with a median follow-up of 52 months, 78% remain alive. The
increased CR rate, and markedly reduced PR
 ve rate presumably
reflect a greater use of postchemotherapy surgery, although only
three patients are recorded as having viable malignancy resected to
achieve CR in the updated series.
TIP has also been evaluated by a German group (Porcu et al,
2000). A totoal of 80 patients failing initial or salvage cisplatin-
based combination chemotherapy were treated with three cycles of
TIP (doses as used by MRC, but ifosfamide 1.2gm
 2 i.v. daily 5)
with G-CSF support. It was planned that all patients would proceed
to high-dose chemotherapy using carboplatin, etoposide and
thiotepa. The response rate to TIP was 11% CR and 29% PR
 ve
(total 40%). In all, 78% of patients proceeded to high-dose therapy.
With a median follow-up of 3 years, 21 patients (26%) were
failure free with 22 alive (26%). This was a more heavily pre-
treated population than ours. Nonetheless, this seems a dis-
appointing result.
The MSKCC Group have published separate data on the salvage
therapy of patients relapsing with a poor prognosis. In total, 37
patients were treated with two cycles of paclitaxel and ifosfamide
at 2-week intervals and accompanied by stem cell harvest. The
patients were then treated with three cycles of high-dose
carboplatin and etoposide at 14–21 day intervals with stem cell
support. Despite the highly adverse prognostic features of this
group, 41% remained failure free at a median follow-up time of 21
2
years. Our results using TIP in a comparable group, with much
shorter follow-up, again appeared inferior.
A number of publications are now available describing
experience with single agents (Motzer et al, 1994; Bokemeyer
et al, 1996, 1999; Sandler et al, 1998; Einhorn et al, 1999;
Kollmannsberger et al, 2002ab) or drug combinations (Miki et al,
2002; Hinton et al, 2002; Madani et al, 2003; Kollmannsberger
et al, 2004) in patients with end-stage and cisplatin-refractory
disease. Paclitaxel, gemcitabine and oxaliplatin have been eval-
uated as single agents, and the combinations paclitaxel and
gemcitabine (Hinton et al, 2002), oxaliplatin and gemcitabine
(Kollmannsberger et al, 2004), cisplatin and irinotecan (Miki et al,
2002) and cisplatin and epirubicin (Madani et al, 2003) as
combinations. Comparison of these regimens is not possible
because of the heterogeneous nature of the groups treated.
However, the achievement of ongoing complete remission in a
proportion of cases receiving all four described drug combinations
is certainly a provocative finding.
How should contemporary patients relapsing after first-line
chemotherapy be treated? There is no definite answer. The single
randomised trial showing no benefit to high-dose treatment has
been criticised as only one cycle of high-dose treatment was used.
Patients in a good prognosis group can still reasonably be treated
with standard-dose salvage regimens. Further prospective rando-
mised trials are indicated but would clearly need to be inter-
national. Entry of these patients into prospective studies wherever
possible is indicated.
In conclusion, our multicentre experience of TIP chemotherapy
demonstrates that a substantial proportion of patients, particularly
those in the MSKCC favourable group, can achieve long-term
FFS. The results of patients with early relapse or those failing to
respond satisfactorily to initial BEP are poor and alter-
native treatment approaches are clearly required. In a future
study, we plan to intensify TIP, firstly by avoiding dose reduc-
tions by use of growth factors and secondly through the addition
of gemcitabine.
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Appendix A1
This study was initiated by the Medical Research Council (now
National Cancer Research Institute) Testicular Cancer Group. The
principal investigators were Professor M Mason (Cardiff) and
Dr GM Mead (Southampton). The trial was coordinated by the
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sMRC Clinical Trials Unit, London (formerly the MRC Cancer
Trials Office, Cambridge, UK); the senior Clinical Trial Manager
was Pat Cook and the trial statistician Sally Stenning. The
following centres and clinicians entered patients into the trial:
Southampton General Hospital/Royal South Hants Hospital
(10): GM Mead, P Simmonds.
Birmingham Oncology Centre (9): MH Cullen.
Royal Marsden Hospital (7): R Huddart, DP Dearnaley.
Guy’s Hospital (5): P Harper.
Cookridge Hospital, Leeds (5): WG Jones (retired).
Mt Vernon Hospital (5): GJS Rustin.
Bristol Oncology Centre (2): JD Graham.
Beatson Oncology Centre, Glasgow (2): P Vasey.
Velindre Hospital, Cardiff (1): J Barber, M Mason.
Aberdeen Royal Infirmary (2): D Bissett, A Hutcheon.
Leicester Royal Infirmary (1): FJ Madden (retired).
Lincoln County Hospital (1): T Sreenivasa.
Walsgrave Hospital, Coventry (1): A Stockdale.
Christie Hospital, Manchester (1): PM Wilkinson.
A phase II trial of TIP
GM Mead et al
184
British Journal of Cancer (2005) 93(2), 178–184 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s